PRESS RELEASE

Biotest AG: Annual General Meeting approves dividend distribution

- Distribution of EUR 0.04 per preferred share

- Broad majority on all agenda items

Dreieich 08 May 2020. At the first ordinary, virtual Annual General Meeting on 08 May 2020, the shareholders of Biotest AG resolved to distribute a dividend. A total of 47.26 % of the share capital was represented. The resolution on the appropriation of the net profit was passed with 99.83% approval for a distribution of € 0.04 per preference share. A total amount of about € 0.8 million will thus be distributed.

The shareholders approved the actions of the members of the Executive Board and the Supervisory Board for the 2019 financial year by a large majority and confirmed all other items on the agenda with a large majority of votes in favour.

The speech of Dr. Michael Ramroth, CEO of Biotest AG, at the Annual General Meeting is available at:
/de/en/investor_relations/shareholders_meeting_2020.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,800 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: 06
Mail:

PR contact
Dirk Neumüller
Phone: 9
Mail:

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.